secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lucid Diagnostics Inc. (LUCD)
CIK:        0001799011
Form:       8-K
Filed at:   2023-04-03T23:59:59+00:00
Accession:  0001493152-23-010538
Event type: regulatory
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MolDX publishes Medicare LCD for esophageal cancer testing; effective May 14, 2023
--------------------------------------------------------------------------------

- Foundational LCD L39256 provides criteria for future coverage of molecular tests like EsoGuard.
- LCD incorporates stakeholder feedback from 2022 draft, aligning with ACG guidelines and non-endoscopic testing.
- Lucid plans to submit EsoGuard for Technical Assessment later this year after clinical utility data completion.
- Company also highlights recent in-network agreement with MultiPlan to expand commercial payer coverage.
- Lucid is a majority-owned subsidiary of PAVmed Inc. (PAVM).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1799011/000149315223010538/0001493152-23-010538-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1799011/000149315223010538/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-010538

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer